Literature DB >> 22496924

Expression of Leukocyte Inhibitory Immunoglobulin-like Transcript 3 Receptors by Ovarian Tumors in Laying Hen Model of Spontaneous Ovarian Cancer.

Mohammad Faisal Khan1, Janice M Bahr, Aparna Yellapa, Pincas Bitterman, Jacques S Abramowicz, Seby L Edassery, Sanjib Basu, Jacob Rotmensch, Animesh Barua.   

Abstract

Attempts to enhance a patient's immune response and ameliorate the poor prognosis of ovarian cancer (OVCA) have largely been unsuccessful owing to the suppressive tumor microenvironment. Leukocyte immunoglobulin-like transcript 3 (ILT3) inhibitory receptors have been implicated in immunosuppression in several malignancies. The expression and role of ILT3 in the progression of ovarian tumors are unknown. This study examined the expression and association of ILT3 in ovarian tumors in laying hens, a spontaneous preclinical model of human OVCA. White Leghorn laying hens were selected by transvaginal ultrasound scanning. Serum and normal ovaries or ovarian tumors were collected. The presence of tumors and the expression of ILT3 were examined by routine histology, immunohistochemistry, Western blot analysis, and reverse transcription-polymerase chain reaction. In addition to stromal immune cell-like cells, the epithelium of the ovarian tumors also expressed ILT3 with significantly high intensity than normal ovaries. Among different subtypes of ovarian carcinomas, serous OVCA showed the highest ILT3 staining intensity, whereas endometrioid OVCA had the lowest intensity. Similar to humans, an immunoreactive protein band of approximately 55 kDa for ILT3 was detected in the ovarian tumors in hens. The patterns of ILT3 protein and messenger RNA expression by ovarian tumors in different subtypes and stages were similar to those of immunohistochemical staining. The results of this study suggest that laying hens may be useful to generate information on ILT3-associated immunosuppression in OVCA. This animal model also offers the opportunity to develop and test anti-ILT3 immunotherapy to enhance antitumor immunity against OVCA in humans.

Entities:  

Year:  2012        PMID: 22496924      PMCID: PMC3323929          DOI: 10.1593/tlo.11328

Source DB:  PubMed          Journal:  Transl Oncol        ISSN: 1936-5233            Impact factor:   4.243


  35 in total

Review 1.  Dendritic cell immunotherapy: mapping the way.

Authors:  Carl G Figdor; I Jolanda M de Vries; W Joost Lesterhuis; Cornelis J M Melief
Journal:  Nat Med       Date:  2004-05       Impact factor: 53.440

2.  The chicken leukocyte receptor complex: a highly diverse multigene family encoding at least six structurally distinct receptor types.

Authors:  Birgit C Viertlboeck; Felix A Habermann; Ramona Schmitt; Martien A M Groenen; Louis Du Pasquier; Thomas W Göbel
Journal:  J Immunol       Date:  2005-07-01       Impact factor: 5.422

Review 3.  Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.

Authors:  Suyu Shu; Alistair J Cochran; Rong-Rong Huang; Donald L Morton; Holden T Maecker
Journal:  Cancer Metastasis Rev       Date:  2006-06       Impact factor: 9.264

4.  Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma.

Authors:  Shuang Wei; Ilona Kryczek; Linhua Zou; Ben Daniel; Pui Cheng; Peter Mottram; Tyler Curiel; Andrzej Lange; Weiping Zou
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

5.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

6.  Characterization of ovarian surface epithelial cells from the hen: a unique model for ovarian cancer.

Authors:  James R Giles; Lisa M Olson; Patricia A Johnson
Journal:  Exp Biol Med (Maywood)       Date:  2006-12

Review 7.  Regulatory T cells in cancer.

Authors:  Marc Beyer; Joachim L Schultze
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

8.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

Review 9.  Transforming growth factor-beta regulation of immune responses.

Authors:  Ming O Li; Yisong Y Wan; Shomyseh Sanjabi; Anna-Karin L Robertson; Richard A Flavell
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

10.  Ovarian cancer. Survival and treatment differences by age.

Authors:  L A Ries
Journal:  Cancer       Date:  1993-01-15       Impact factor: 6.860

View more
  10 in total

1.  Expression of death receptor 6 by ovarian tumors in laying hens, a preclinical model of spontaneous ovarian cancer.

Authors:  Animesh Barua; Aparna Yellapa; Janice M Bahr; Jacques S Abramowicz; Seby L Edassery; Sanjib Basu; Jacob Rotmensch; Pincas Bitterman
Journal:  Transl Oncol       Date:  2012-08-01       Impact factor: 4.243

Review 2.  Leukocyte immunoglobulin-like receptors in human diseases: an overview of their distribution, function, and potential application for immunotherapies.

Authors:  Jilu Zhang; Sunny Mai; Hui-Ming Chen; Kyeongah Kang; Xian Chang Li; Shu-Hsia Chen; Ping-Ying Pan
Journal:  J Leukoc Biol       Date:  2017-03-28       Impact factor: 4.962

3.  Detection of Cannabinoid Receptor Expression by Endometriotic Lesions in Women with Endometriosis as an Alternative to Opioid-Based Pain Medication.

Authors:  Sarah Allam; Elizabeth Paris; Itzel Lazcano; Pincas Bitterman; Sanjib Basu; James O'Donnell; Animesh Barua
Journal:  J Immunol Res       Date:  2022-06-02       Impact factor: 4.493

4.  Immunoglobulin-like transcript 4 promotes tumor progression and metastasis and up-regulates VEGF-C expression via ERK signaling pathway in non-small cell lung cancer.

Authors:  Pei Zhang; Xiaosun Guo; Juan Li; Shuwen Yu; Linlin Wang; Guosheng Jiang; Dong Yang; Zhaolong Wei; Nan Zhang; Jie Liu; Yuping Sun
Journal:  Oncotarget       Date:  2015-05-30

5.  Interleukin 16- (IL-16-) Targeted Ultrasound Imaging Agent Improves Detection of Ovarian Tumors in Laying Hens, a Preclinical Model of Spontaneous Ovarian Cancer.

Authors:  Animesh Barua; Aparna Yellapa; Janice M Bahr; Malavika K Adur; Chet W Utterback; Pincas Bitterman; Sanjib Basu; Sameer Sharma; Jacques S Abramowicz
Journal:  Biomed Res Int       Date:  2015-06-16       Impact factor: 3.411

Review 6.  Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer.

Authors:  Mi Deng; Heyu Chen; Xiaoye Liu; Ryan Huang; Yubo He; Byounggyu Yoo; Jingjing Xie; Samuel John; Ningyan Zhang; Zhiqiang An; Cheng Cheng Zhang
Journal:  Antib Ther       Date:  2021-02-09

7.  Changes in IL-16 Expression in the Ovary during Aging and Its Potential Consequences to Ovarian Pathology.

Authors:  Jessica Ramirez; Pincas Bitterman; Sanjib Basu; Animesh Barua
Journal:  J Immunol Res       Date:  2022-04-26       Impact factor: 4.493

Review 8.  Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors.

Authors:  Xunlei Kang; Jaehyup Kim; Mi Deng; Samuel John; Heyu Chen; Guojin Wu; Hiep Phan; Cheng Cheng Zhang
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

9.  Association of Immunosuppression with DR6 Expression during the Development and Progression of Spontaneous Ovarian Cancer in Laying Hen Model.

Authors:  Sa'Rah McNeal; Pincas Bitterman; Janice M Bahr; Seby L Edassery; Jacques S Abramowicz; Sanjib Basu; Animesh Barua
Journal:  J Immunol Res       Date:  2016-08-04       Impact factor: 4.818

Review 10.  Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics.

Authors:  Curtis W McCloskey; Galaxia M Rodriguez; Kristianne J C Galpin; Barbara C Vanderhyden
Journal:  Cancers (Basel)       Date:  2018-07-26       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.